Temsirolimus
Orphan Drug Cold Chain RequiredFDA Approved
Description
Temsirolimus is an mTOR inhibitor used in the treatment of advanced renal cell carcinoma. It inhibits mTOR, a protein that regulates cell growth, proliferation, and survival.
Indications & Therapeutic Use
Advanced renal cell carcinoma
Linked Diseases:
renal cell carcinoma
C64D002292
Global Availability (5 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Temsirolimus
| Generic Name | Temsirolimus |
| Brands | 1 brand available |
| Active Ingredient | Temsirolimus |
| Drug Class | Advanced renal cell carcinoma |
| Manufacturer | Pfizer |
| Dosage Forms | IV infusion |
| Medical Code | L01XE09 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Reg. Status | FDA Approved |
| Countries | 5 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations6 Validated Nodes